cytidine
Small moleculeexperimental
Cytidine (symbol C or Cyd) is a nucleoside molecule that is formed when cytosine is attached to a ribose ring (also known as a ribofuranose) via a β-N1-glycosidic bond. Cytidine is a component of RNA. It is a white water-soluble solid that is only slightly soluble in ethanol. — Wikipedia
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2004 (NCT00854737)
Timeline
Indications
Mechanism of action
- DNADISRUPTING AGENT
DNA disrupting agent
Chemistry & pharmacology
Loading structure…
SMILES
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1- Mol. weight
- 243.22 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCytidine ↗
- ChEMBLCHEMBL95606 ↗
Also known as
- cytidine
- cytidine
- cytidine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07304453 | Phase 2 | Jan 7, 2024 | Karbala University, Kufa University |
| NCT04499755 | Phase 3 | Jun 1, 2020 | Kafrelsheikh University, Tanta University |
| NCT01543139 | N/A | Oct 1, 2009 | Seoul National University |
| NCT00854737 | Phase 2 | Jul 1, 2004 | Mclean Hospital, Stanley Medical Research Institute |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kafrelsheikh University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Karbala University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Kufa University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Mclean Hospital | Academic/Hospital | 1 | 1 | 1 | 2004 |
| Seoul National University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Stanley Medical Research Institute | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Tanta University | Academic/Hospital | 1 | 1 | 1 | 2020 |
7 organizations
Page 1 / 1